Skip to main navigation
Close
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Blog
Apr 16, 2018
| Erica Klinger
Restricted Access Drug Programs Impeding Patient Access to Generic Drugs: Myths and Facts Regarding Maine LD 1280
Fact Sheet
Apr 16, 2018
| Erica Klinger
Oppose Louisiana House Bill 243
Press Release
Apr 13, 2018
| Rachel Schwartz
AAM Statement on U.S. Court of Appeals Ruling on Maryland HB 631
Blog
Apr 13, 2018
| Erik Komendant
Cotton-McCaskill PACED Act Would Help Patients Gain Access to More Affordable Generics
Infographic
Apr 13, 2018
| Erica Klinger
Protect Generic Rx Savings for Maryland Patients and Taxpayers
Press Release
Apr 11, 2018
| Rachel Schwartz
AAM Receives Two ASAE 2018 Gold Circle Awards
Video
Apr 10, 2018
| Erica Klinger
Skyrocketing Brand Drug Prices Are a Threat to Everyone
Press Release
Apr 9, 2018
| Rachel Schwartz
AAM Launches Code of Business Ethics
Blog
Apr 9, 2018
| Jeff Francer
AAM Has Adopted a Code of Business Ethics. Here’s What That Means.
Press Release
Apr 4, 2018
| Rachel Schwartz
AAM Statement on China Tariffs
Blog
Apr 1, 2018
| Jewel Smith
Why Membership Matters
Press Release
Mar 28, 2018
| Rachel Schwartz
AAM Statement on Generic and Biosimilar Drugmaker Inability to Acquire Samples
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2024
GRx+Biosims 2023
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action